Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
Paul Lorigan(Manchester Academic Health Science Centre), Jean‐Yves Blay(Université Claude Bernard Lyon 1), John Radford(Manchester Academic Health Science Centre), Zsuzsa Pápai(European Organisation for Research and Treatment of Cancer), M. M. Van Glabbeke(European Organisation for Research and Treatment of Cancer), Michael Leahy(The Christie NHS Foundation Trust), Jaap Verweij(Deutz (Germany)), Anne Kirkpatrick(European Organisation for Research and Treatment of Cancer), Axel Le Cesne(Institut Gustave Roussy), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Pancras C.W. Hogendoorn(Vrije Universiteit Brussel)
Cited by 256
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k